Literature DB >> 3327579

Hypogammaglobulinemia: therapeutic rationale.

A A Long1, J A Denburg, P B Dent.   

Abstract

Hypogammaglobulinemia is a feature of several B-cell disorders and is manifested clinically by recurrent infection, most commonly chronic upper and lower respiratory tract disease. Immunoglobulin replacement therapy is available, with at least four different routes of administration. There are as yet no convincing data that allow comparison of the cost-effectiveness of these methods. However, by individualizing therapy for each patient, it is possible to prevent life-threatening acute infections, reduce the severity of chronic upper and lower respiratory tract disease, improve pulmonary function and achieve normal levels of IgG. These are the currently acceptable goals of therapy in patients with hypogammaglobulinemia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3327579      PMCID: PMC1267348     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  36 in total

1.  A national registry for primary immunodeficiency syndromes in Italy: a report for the period 1972-1982.

Authors:  G Luzi; L Businco; F Aiuti
Journal:  Birth Defects Orig Artic Ser       Date:  1983

2.  Individualization of gamma globulin dosage in patients with humoral immunodeficiency.

Authors:  R I Schiff; C Rudd; R Johnson; R H Buckley
Journal:  Birth Defects Orig Artic Ser       Date:  1983

Review 3.  Treatment of defects of humoral immunity.

Authors:  M Eibl
Journal:  Birth Defects Orig Artic Ser       Date:  1983

Review 4.  Immunodeficiency.

Authors:  R H Buckley
Journal:  J Allergy Clin Immunol       Date:  1983-12       Impact factor: 10.793

5.  Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial.

Authors:  A J Ammann; R F Ashman; R H Buckley; W R Hardie; H J Krantmann; J Nelson; H Ochs; E R Stiehm; T Tiller; D W Wara; R Wedgwood
Journal:  Clin Immunol Immunopathol       Date:  1982-01

Review 6.  The primary immunodeficiencies. (2).

Authors:  F S Rosen; M D Cooper; R J Wedgwood
Journal:  N Engl J Med       Date:  1984-08-02       Impact factor: 91.245

7.  Use of intravenous immunoglobulin in chronic lymphocytic leukemia.

Authors:  E C Besa
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

8.  Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases.

Authors:  H D Ochs; S H Fischer; R J Wedgwood; D W Wara; M J Cowan; A J Ammann; A Saxon; M D Budinger; R U Allred; R H Rousell
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

9.  Phase I study of intravenous gamma globulin in multiple myeloma.

Authors:  D S Gordon; E B Hearn; T J Spira; C B Reimer; D J Phillips; C Schable
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

10.  Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease.

Authors:  C Cunningham-Rundles; F P Siegal; E M Smithwick; A Lion-Boulé; S Cunningham-Rundles; J O'Malley; S Barandun; R A Good
Journal:  Ann Intern Med       Date:  1984-10       Impact factor: 25.391

View more
  4 in total

1.  Intravenous IgG: A New Therapeutic Tool.

Authors:  L K Boshkov; J G Kelton
Journal:  Can Fam Physician       Date:  1988-11       Impact factor: 3.275

Review 2.  Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.

Authors:  Richard L Wasserman
Journal:  J Clin Immunol       Date:  2012-07-25       Impact factor: 8.317

3.  Localised pulmonary resection for bronchiectasis in hypogammaglobulinaemic patients.

Authors:  A J Cohen; C Roifman; J Brendan; M Mullen; B Reid; G Weisbrod; G P Downey
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

Review 4.  Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency.

Authors:  Stephen Jolles
Journal:  Immunotargets Ther       Date:  2013-09-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.